AAPL325.90-0.70 (-0.21%) ▼|ABBV255.44+2.06 (+0.81%) ▲|ABT101.56-0.10 (-0.10%) ▼|ACN142.90-1.83 (-1.26%) ▼|ADBE229.06-5.68 (-2.42%) ▼|AMAT560.93+35.23 (+6.70%) ▲|AMD525.38+21.81 (+4.33%) ▲|AMGN367.54+3.37 (+0.93%) ▲|AMT164.90-2.16 (-1.29%) ▼|AMZN247.17-2.82 (-1.13%) ▼|AVGO382.16+4.00 (+1.06%) ▲|AXP351.94+0.01 (+0.00%) ▲|BA210.80+1.32 (+0.63%) ▲|BAC60.79+0.37 (+0.61%) ▲|BKNG178.79-0.66 (-0.37%) ▼|BLK1,059.56+5.45 (+0.52%) ▲|BMY60.53+0.37 (+0.62%) ▲|BNY158.42+1.49 (+0.95%) ▲|BRK-B490.08-1.17 (-0.24%) ▼|C131.93+3.21 (+2.49%) ▲|CAT881.98+17.68 (+2.05%) ▲|CL91.04-0.90 (-0.97%) ▼|CMCSA23.82+0.04 (+0.15%) ▲|COF205.51-1.26 (-0.61%) ▼|COP116.63+0.95 (+0.82%) ▲|COST930.60-5.20 (-0.56%) ▼|CRM170.78-3.01 (-1.73%) ▼|CSCO111.78+1.08 (+0.98%) ▲|CVS109.00+1.39 (+1.29%) ▲|CVX190.10+0.39 (+0.21%) ▲|DE585.12-0.89 (-0.15%) ▼|DHR175.59-25.53 (-12.69%) ▼|DIS96.29-0.12 (-0.12%) ▼|DUK125.15-0.70 (-0.56%) ▼|EMR137.79+1.21 (+0.89%) ▲|FDX314.98+8.76 (+2.86%) ▲|GD372.84+2.24 (+0.60%) ▲|GE344.68+3.38 (+0.99%) ▲|GEV1,085.71+6.53 (+0.61%) ▲|GILD132.48-0.73 (-0.55%) ▼|GM78.65+2.85 (+3.76%) ▲|GOOG348.71-2.66 (-0.76%) ▼|GOOGL349.30-2.69 (-0.76%) ▼|GS1,079.21+24.18 (+2.29%) ▲|HD329.22-3.82 (-1.15%) ▼|HON229.48+3.30 (+1.46%) ▲|IBM210.63-2.37 (-1.11%) ▼|INTC102.63+5.57 (+5.74%) ▲|INTU289.31-4.51 (-1.54%) ▼|ISRG361.07+7.90 (+2.24%) ▲|JNJ250.09+1.27 (+0.51%) ▲|JPM342.90+4.03 (+1.19%) ▲|KO81.86-0.27 (-0.32%) ▼|LIN508.76-3.29 (-0.64%) ▼|LLY1,162.73+15.83 (+1.38%) ▲|LMT504.54-5.00 (-0.98%) ▼|LOW202.62-2.09 (-1.02%) ▼|LRCX317.36+10.60 (+3.45%) ▲|MA542.28-5.16 (-0.94%) ▼|MCD264.86-2.78 (-1.04%) ▼|MDLZ59.50-0.77 (-1.28%) ▼|MDT82.86-0.43 (-0.52%) ▼|META647.09+1.24 (+0.19%) ▲|MMM174.64+15.53 (+9.76%) ▲|MO73.85-0.81 (-1.08%) ▼|MRK126.02+1.62 (+1.30%) ▲|MS215.71+4.77 (+2.26%) ▲|MSFT400.11-2.18 (-0.54%) ▼|MU924.05+58.59 (+6.77%) ▲|NEE87.87-0.13 (-0.14%) ▼|NFLX67.68+0.08 (+0.12%) ▲|NKE43.10-0.38 (-0.86%) ▼|NOW103.09-1.61 (-1.54%) ▼|NVDA205.21+1.93 (+0.95%) ▲|ORCL125.23+3.85 (+3.17%) ▲|PEP134.73-0.73 (-0.54%) ▼|PFE24.95+0.20 (+0.81%) ▲|PG147.75-1.38 (-0.93%) ▼|PLTR133.72-1.13 (-0.84%) ▼|PM191.29-1.43 (-0.74%) ▼|QCOM171.95+1.63 (+0.96%) ▲|RTX196.69+2.25 (+1.16%) ▲|SBUX104.78-0.04 (-0.03%) ▼|SCHW102.79+0.25 (+0.24%) ▲|SO93.71-0.76 (-0.80%) ▼|SPG229.40+1.21 (+0.53%) ▲|T22.01+0.06 (+0.25%) ▲|TMO519.19-7.04 (-1.34%) ▼|TMUS192.53-3.11 (-1.59%) ▼|TSLA381.19+11.62 (+3.14%) ▲|TXN291.73+7.66 (+2.69%) ▲|UBER71.95-0.23 (-0.31%) ▼|UNH432.29+10.74 (+2.55%) ▲|UNP294.88-1.37 (-0.46%) ▼|UPS115.44+2.29 (+2.02%) ▲|USB63.16+0.02 (+0.02%) ▲|V357.72-2.85 (-0.79%) ▼|VZ43.35-0.15 (-0.34%) ▼|WFC86.94+0.61 (+0.71%) ▲|WMT111.17-1.03 (-0.92%) ▼|XOM150.40+2.04 (+1.37%) ▲|AAPL325.90-0.70 (-0.21%) ▼|ABBV255.44+2.06 (+0.81%) ▲|ABT101.56-0.10 (-0.10%) ▼|ACN142.90-1.83 (-1.26%) ▼|ADBE229.06-5.68 (-2.42%) ▼|AMAT560.93+35.23 (+6.70%) ▲|AMD525.38+21.81 (+4.33%) ▲|AMGN367.54+3.37 (+0.93%) ▲|AMT164.90-2.16 (-1.29%) ▼|AMZN247.17-2.82 (-1.13%) ▼|AVGO382.16+4.00 (+1.06%) ▲|AXP351.94+0.01 (+0.00%) ▲|BA210.80+1.32 (+0.63%) ▲|BAC60.79+0.37 (+0.61%) ▲|BKNG178.79-0.66 (-0.37%) ▼|BLK1,059.56+5.45 (+0.52%) ▲|BMY60.53+0.37 (+0.62%) ▲|BNY158.42+1.49 (+0.95%) ▲|BRK-B490.08-1.17 (-0.24%) ▼|C131.93+3.21 (+2.49%) ▲|CAT881.98+17.68 (+2.05%) ▲|CL91.04-0.90 (-0.97%) ▼|CMCSA23.82+0.04 (+0.15%) ▲|COF205.51-1.26 (-0.61%) ▼|COP116.63+0.95 (+0.82%) ▲|COST930.60-5.20 (-0.56%) ▼|CRM170.78-3.01 (-1.73%) ▼|CSCO111.78+1.08 (+0.98%) ▲|CVS109.00+1.39 (+1.29%) ▲|CVX190.10+0.39 (+0.21%) ▲|DE585.12-0.89 (-0.15%) ▼|DHR175.59-25.53 (-12.69%) ▼|DIS96.29-0.12 (-0.12%) ▼|DUK125.15-0.70 (-0.56%) ▼|EMR137.79+1.21 (+0.89%) ▲|FDX314.98+8.76 (+2.86%) ▲|GD372.84+2.24 (+0.60%) ▲|GE344.68+3.38 (+0.99%) ▲|GEV1,085.71+6.53 (+0.61%) ▲|GILD132.48-0.73 (-0.55%) ▼|GM78.65+2.85 (+3.76%) ▲|GOOG348.71-2.66 (-0.76%) ▼|GOOGL349.30-2.69 (-0.76%) ▼|GS1,079.21+24.18 (+2.29%) ▲|HD329.22-3.82 (-1.15%) ▼|HON229.48+3.30 (+1.46%) ▲|IBM210.63-2.37 (-1.11%) ▼|INTC102.63+5.57 (+5.74%) ▲|INTU289.31-4.51 (-1.54%) ▼|ISRG361.07+7.90 (+2.24%) ▲|JNJ250.09+1.27 (+0.51%) ▲|JPM342.90+4.03 (+1.19%) ▲|KO81.86-0.27 (-0.32%) ▼|LIN508.76-3.29 (-0.64%) ▼|LLY1,162.73+15.83 (+1.38%) ▲|LMT504.54-5.00 (-0.98%) ▼|LOW202.62-2.09 (-1.02%) ▼|LRCX317.36+10.60 (+3.45%) ▲|MA542.28-5.16 (-0.94%) ▼|MCD264.86-2.78 (-1.04%) ▼|MDLZ59.50-0.77 (-1.28%) ▼|MDT82.86-0.43 (-0.52%) ▼|META647.09+1.24 (+0.19%) ▲|MMM174.64+15.53 (+9.76%) ▲|MO73.85-0.81 (-1.08%) ▼|MRK126.02+1.62 (+1.30%) ▲|MS215.71+4.77 (+2.26%) ▲|MSFT400.11-2.18 (-0.54%) ▼|MU924.05+58.59 (+6.77%) ▲|NEE87.87-0.13 (-0.14%) ▼|NFLX67.68+0.08 (+0.12%) ▲|NKE43.10-0.38 (-0.86%) ▼|NOW103.09-1.61 (-1.54%) ▼|NVDA205.21+1.93 (+0.95%) ▲|ORCL125.23+3.85 (+3.17%) ▲|PEP134.73-0.73 (-0.54%) ▼|PFE24.95+0.20 (+0.81%) ▲|PG147.75-1.38 (-0.93%) ▼|PLTR133.72-1.13 (-0.84%) ▼|PM191.29-1.43 (-0.74%) ▼|QCOM171.95+1.63 (+0.96%) ▲|RTX196.69+2.25 (+1.16%) ▲|SBUX104.78-0.04 (-0.03%) ▼|SCHW102.79+0.25 (+0.24%) ▲|SO93.71-0.76 (-0.80%) ▼|SPG229.40+1.21 (+0.53%) ▲|T22.01+0.06 (+0.25%) ▲|TMO519.19-7.04 (-1.34%) ▼|TMUS192.53-3.11 (-1.59%) ▼|TSLA381.19+11.62 (+3.14%) ▲|TXN291.73+7.66 (+2.69%) ▲|UBER71.95-0.23 (-0.31%) ▼|UNH432.29+10.74 (+2.55%) ▲|UNP294.88-1.37 (-0.46%) ▼|UPS115.44+2.29 (+2.02%) ▲|USB63.16+0.02 (+0.02%) ▲|V357.72-2.85 (-0.79%) ▼|VZ43.35-0.15 (-0.34%) ▼|WFC86.94+0.61 (+0.71%) ▲|WMT111.17-1.03 (-0.92%) ▼|XOM150.40+2.04 (+1.37%) ▲|
24.8 C
New York
Tuesday, July 21, 2026

Tag: kidney disease

newssourceFORcompanyinformationcontent1releasesmarket

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney diseaseZHUBEI CITY, Taiwan and RALEIGH, N.C.,...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

New Health Economic Evidence Shows Health & Cost Benefits When Starting Dialysis at Home

New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

Veterinarian-Founded Startup Prodogi Launches First Oral Health Strip for Dogs with Slow Dissolve Technology

First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...

Veterinarian-Founded Startup Prodogi Launches First Oral Health Strip for Dogs with Slow Dissolve Technology

First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...

GameStop’s Viral “Staplegate” Auction Transformed an Unexpected Incident into a Powerful Philanthropic Initiative

Charity auction raises $250,000 for Children's Miracle Network Hospitals NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Children's Miracle Network Hospitals (CMN Hospitals) announced that...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. – UNCY

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

XORTX Completes USD $114,500 Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsKidney disease

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers